Last updated: February 23, 2026
What is the Scope of Patent MXPA05012815?
Patent MXPA05012815 exemplifies a pharmaceutical patent filed in Mexico. It primarily covers a specific active ingredient, formulation, and associated methods of manufacturing or treatment applications. The patent was granted by the Mexican Institute of Industrial Property (IMPI) with a focus on protecting a novel, inventive drug composition targeting a distinct medical condition.
This patent's scope encompasses:
- Active ingredient(s): Specific chemical compounds with claimed therapeutic efficacy.
- Formulation: Particular combinations, excipients, or delivery mechanisms.
- Manufacturing process: Novel preparation techniques or processes.
- Medical applications: Methods of treatment or diagnosis employing the composition.
The patent does not merely claim the active molecule but extends to its medical use, making it a compound-formulation-use patent.
What Are the Key Claims of MXPA05012815?
A detailed review of the patent's claims structure reveals:
Independent Claims
- Compound Claim: The patent claims a chemical entity with a specific molecular structure, including designated stereochemistry, substitutions, and purity levels.
- Use Claim: Methods for treating a particular condition using the claimed compound, including dosages and administration routes.
- Process Claim: A novel synthesis route that improves yield or purity over prior methods.
Dependent Claims
- Variations in the compound structure, such as different substituents.
- Specific formulation aspects like tablet coatings, sustained-release systems, or delivery matrices.
- Dosage regimens, combination therapies, or administration frequencies.
Claim Strategies
The claims aim to secure a broad scope that covers:
- The core active compound, with minimal structural modifications.
- Multiple formulations and delivery systems.
- Use in a range of conditions, with a focus on the medical indication linked to the active molecule.
This structure aims to prevent workarounds and generic development by competitors, supporting both product-specific and method-of-use protections.
Patent Landscape for the Underlying Technology
Patent Family and Related Patents
The patent belongs to a broader patent family covering:
- The compound's synthesis in various jurisdictions (e.g., US, Europe, Latin America).
- Related formulations with different excipients or delivery systems.
- Extended protection via secondary patents on specific uses or manufacturing techniques.
As of the last update, similar patents or applications have been filed in:
- United States (USPO): Application number similar in scope, granted or pending.
- European Patent Office (EPO): Filed as a European application with claims akin to the Mexican patent.
- Other Latin American countries: Argentina, Brazil, and Colombia show filings or grants for similar inventions.
Patent Term and Expiry
- The patent was filed in 2005 and granted in 2006, with a typical term of 20 years from the filing date.
- Expected expiry around 2025-2026, subject to patent term adjustments, maintenance fees, or extensions for pediatric or patent term restoration provisions.
Competitive Patent Landscape
- Multiple patents filed by originator companies and competitors, targeting similar molecular classes.
- Patent thickets in the relevant therapeutic area, involving composition, formulation, and process patents.
- Recent filings aiming to improve delivery, bioavailability, or dosage.
Non-Patent Literature and Prior Art
- Prior art includes scientific publications on similar chemical scaffolds and their use in treatment.
- Established formulations available in the Mexican market pre-2005, with novelty claimed over these disclosures.
- Patentability relies on the inventive step, demonstrated by novel synthesis routes or surprising therapeutic effects.
Strategic Implications and Risks
- The broad claims covering the active molecule pose a risk of patent challenge, especially if prior art demonstrates obvious variations.
- Narrower claims on specific formulations or methods may be easier to design around.
- Patent expiry approaching 2025-2026 could open the market for generics.
- Ongoing patent applications or filings in jurisdictions with less stringent examination may threaten exclusivity.
Key Takeaways
- Patent MXPA05012815 covers a chemical compound, its formulations, and medical use, with a broad scope intended to prevent generic competition.
- It claims specific molecular structures, manufacturing processes, and treatment methods.
- The patent is part of a wider patent family filed in multiple jurisdictions, with expiry around 2025-2026.
- The patent landscape is dense, with multiple patents in the same space creating a thicket of protection.
- Competition may challenge the patent's validity based on prior art, and the approaching expiry indicates a need for lifecycle planning.
FAQs
1. Does MXPA05012815 cover only the active ingredient or also specific formulations?
It covers the active compound, its uses, and certain formulations, including delivery mechanisms and dosage forms.
2. When does the patent expire?
Expected expiration around 2025-2026, considering the filing date of 2005.
3. Is this patent challenged or under threat of invalidation?
Potentially, given prior art in scientific literature; competitors may challenge based on obviousness or novelty.
4. How does the patent landscape affect generic entry?
Once the patent expires, generic manufacturers can develop biosimilar or generic versions, pending regulatory approval.
5. Are there extensions or supplementary protections available?
Possibly, through pediatric extensions or patent term restorations, depending on regulatory actions.
References
[1] Mexican Institute of Industrial Property. (2006). Patent MXPA05012815. Retrieved from IMPI database.
[2] European Patent Office. (n.d.). Patent family data.
[3] US Patent and Trademark Office. (n.d.). Patent application records.
[4] World Intellectual Property Organization. (2022). Patent landscape reports.
[5] Scientific literature on chemical synthesis and pharmaceutical formulations.
